Candida in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Pappas, P G ^a   Silveira, F P ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal prophylaxis; Antifungals; Candida epidemiology; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ABSCESS; ANASTOMOSIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CENTRAL VENOUS CATHETER; CEREBROSPINAL FLUID; COMORBIDITY; CYSTITIS; DEVICE REMOVAL; DIAGNOSTIC PROCEDURE; DIALYSIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL COLONIZATION; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RATE; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER GRAFT; LUNG TRANSPLANTATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PICHIA GUILLIERMONDII; PLEURA FLUID; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; PULMONARY CANDIDIASIS; PYELONEPHRITIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STEM CELL TRANSPLANTATION; TRACHEOBRONCHITIS; TREATMENT DURATION; TREATMENT FAILURE; URINARY TRACT INFECTION; VIRUS IDENTIFICATION; VIRUS ISOLATION;

ANTIFUNGAL AGENTS; CANDIDIASIS; HUMANS; ORGAN TRANSPLANTATION;

EID: 72949102455     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02909.x     Document Type: Review

References (70)

1. Pappas PG, Alexander BA, Andes D et al. Invasive fungal infections among organ transplant recipients in the United States: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (in press).
2. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007 45 : 305 320.
3. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999 1 : 229 236.
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007 20 : 133 163.
5. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000 181 : 309 316.
6. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995 59 : 851 859.
7. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994 170 : 644 652.
8. Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg 1996 183 : 408 410.
9. Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006 7 : 297 305.
10. Berenguer J, Buck M, Witebsky F et al. Lysis-centrifugation blood cultures in the detection of proven invasive candidiasis: Disseminated versus single organ infection. Diagn Microbiol Infect Dis 1993 17 : 103 109.
11. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1->3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 41 : 654 659.
12. Obayashi T, Negishi K, Svzvki T, Funata N. Reappraisal of the serum (1->3)-beta-d-glucan based assay for the diagnosis of invasive fungal infections - A study based on autopsy cases from 6 years. Clin Infect Dis 2008 46 : 1864 1870.
13. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004 39 : 199 205. (Pubitemid 38971490)
14. Marr KA, Balajce SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004 190 : 641 649.
15. Wilson DA, Joyce MJ, Hall LS et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 2005 43 : 2909 2912.
16. Shibata A, Kaneko T, Makimura K et al. Comparative study of ability for growth support and species differentiation by colony features on commercial chromogenic agar, Pourmedia Vi Candida and CHROMagar Candida. Nippon Ishinkin Gakkai Zasshi 2008 49 : 33 38.
17. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 48 : 503 535.
18. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002 49 (Suppl 1 37 41. (Pubitemid 34162655)
19. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26 : 1383 1396.
20. Wingard JR. Lipid formulations of amphotericins: Are you a lumper or a splitter? Clin Infect Dis 2002 35 : 891 895.
21. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 331 : 1325 1330.
22. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003 36 : 1221 1228.
23. Nguyen MH, Peacock JE Jr., Tanner DC et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995 155 : 2429 2435.
24. Anaissie EJ, Vartivarian SE, Abi-Said D et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996 101 : 170 176.
25. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double- blind trial. Lancet 2007 369 : 1519 1527.
26. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005 43 : 3884 3889.
27. Wildfeuer A, Laufen H, Schmalreck AF, Yeates RA. Fluconazole: Comparison of pharmacokinetics, therapy, and in vitro susceptibility. Mycoses 1997 40 : 259 265.
28. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004 122 : 42 47.
29. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 37 : 728 732.
30. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006 27 : 274 284.
31. Lipp HP. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses 2008 51 (Suppl 1 7 18.
32. Kauffman CA, Carver PL. Update on echinocandins. Semin Respir Crit Care Med 2008 29 : 211 219.
33. Bennett JE. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006 355 : 1154 1159.
34. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 : 1570 1572.
35. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 47 : 2788 2795.
36. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008 46 : 201 211.
37. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006 20 : 485 506.
38. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005 49 : 3640 3645.
39. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006 43 : 25 31.
40. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 2029.
41. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 356 : 2472 2482.
42. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007 45 : 883 893.
43. Walsh TJ. Echinocandins-an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002 347 : 2070 2072.
44. Weiderhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, spectrum, and clinical efficacy. Expert Opin Investig Drugs 2003 12 : 1313 1333.
45. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet 2005 366 : 1435 1442.
46. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995 21 : 994 996.
47. Nucci M, Anaissie E. Revisiting the source of candidemia: Skin or gut? Clin Infect Dis 2001 33 : 1959 1967.
48. Betts R, Glasmacher A, Maertens J et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006 106 : 466 473.
49. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999 340 : 764 771. (Pubitemid 29114295)
50. Safdar N, Slattery WR, Knasinski V et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 2005 40 : 1413 1421.
51. Kauffman CA, Vazquez JA, Sobel JD et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000 30 : 14 18.
52. Jacobs LG, Skidmore EA, Cardoso LA, Ziv F. Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections.
53. Rello J, Esandi ME, Diaz E, Mariscal D, Gallego M, Valles J. The role of Candida sp. isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998 114 : 146 149.
54. el-Ebiary M, Torres A, Fabregas N et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997 156 : 583 590. (Pubitemid 27351999)
55. Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC. Candida sp. isolated from bronchoalveolar lavage: Clinical significance in critically ill trauma patients. Intensive Care Med 2006 32 : 599 603.
56. Pappas PG, Andes D, Schuster M et al. Invasive fungal infections in low-risk liver transplant recipients: A multi-center prospective observational study. Am J Transplant 2006 6 : 386 391.
57. Arnow PM, Carandang GC, Zabner R, Irwin ME. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996 22 : 997 1003.
58. Hellinger WC, Yao JD, Alvarez S et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002 73 : 1904 1909.
59. Hjortrup A, Rasmussen A, Hansen BA et al. Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination. Transplant Proc 1997 29 : 3106 3110.
60. Wiesner RH, Hermans PE, Rakela J et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988 45 : 570 574.
61. Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996 174 : 583 588.
62. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999 131 : 729 737.
63. Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David CW. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: A prospective, randomized, double-blind study. Transplantation 2003 76 : 977 983.
64. Castroagudin JF, Ponton C, Bustamante M et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005 37 : 3965 3967.
65. Lorf T, Braun F, Ruchel R, Muller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999 42 : 47 53. (Pubitemid 29256326)
66. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 1995 59 : 45 50.
67. Fortun J, Martin-Davila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009 87 : 424 435.
68. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transplant 2006 12 : 850 858.
69. Kusne S, Furukawa H, bu-Elmagd K et al. Infectious complications after small bowel transplantation in adults: An update. Transplant Proc 1996 28 : 2761 2762.
70. Guaraldi G, Cocchi S, Codeluppi M et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 2005 80 : 1742 1748.